Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
10-30-2020

Beyond just a tight fortress: Contribution of stroma to epithelialmesenchymal transition in pancreatic cancer
Ashenafi Bulle
Kian-Huat Lim

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Signal Transduction and Targeted Therapy

REVIEW ARTICLE

www.nature.com/sigtrans

OPEN

Beyond just a tight fortress: contribution of stroma to
epithelial-mesenchymal transition in pancreatic cancer
Ashenaﬁ Bulle1 and Kian-Huat Lim

1

1234567890();,:

Novel effective treatment is direly needed for patients with pancreatic ductal adenocarcinoma (PDAC). Therapeutics that target the
driver mutations, especially the KRAS oncoprotein and its effector cascades, have been ineffective. It is increasing clear that the
extensive ﬁbro-inﬂammatory stroma (or desmoplasia) of PDAC plays an active role in the progression and therapeutic resistance of
PDAC. The desmoplastic stroma is composed of dense extracellular matrix (ECM) deposited mainly by the cancer-associatedﬁbroblasts (CAFs) and inﬁltrated with various types of immune cells. The dense ECM functions as a physical barrier that limits tumor
vasculatures and distribution of therapeutics to PDAC cells. In addition, mounting evidence have demonstrated that both CAFs and
ECM promote PDAC cells aggressiveness through multiple mechanisms, particularly engagement of the epithelial-mesenchymal
transition (EMT) program. Acquisition of a mesenchymal-like phenotype renders PDAC cells more invasive and resistant to therapyinduced apoptosis. Here, we critically review seminal and recent articles on the signaling mechanisms by which each stromal
element promotes EMT in PDAC. We discussed the experimental models that are currently employed and best suited to study EMT
in PDAC, which are instrumental in increasing the chance of successful clinical translation.
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BACKGROUND
The aggressive nature of pancreatic ductal adenocarcinoma
(PDAC) is driven intrinsically by powerful genetic mutations and
extrinsically by a highly ﬁbro-inﬂammatory (or desmoplastic)
stroma, which typically constitutes up to 80–85% of the tumor
bulk. The stroma consists of a dense acellular extracellular matrix
(ECM) which is inﬁltrated with heterogeneous populations of
cancer-associated-ﬁbroblasts (CAFs), immune cells and endothelial
cells.1 Work in the last two decades has now established that the
PDAC stroma is not functionally inert, but instead actively shapes
the behavior of PDAC cells and contribute to treatment resistance.
The dense ECM creates a high-pressured barrier that collapses
blood vessels, limiting the delivery and diffusion of oxygen,
nutrients, and therapeutics to PDAC cells. The ensuing hypoxic
and nutrient-poor tumor microenvironment (TME) also serves as a
cradle for highly resilient PDAC cells that are metabolically
adapted to this inhospitable environment.2,3 In addition, CAFs
secrete various chemokines and cytokines that enhance tumor
progression and therapeutic resistance. A critical pathophysiological process that associates PDAC cells with these feats is
epithelial-mesenchymal transition (EMT). During the process of
EMT, cancer cells loss epithelial markers such as E-cadherin, certain
cytokeratins, occludin, and claudin, and gain mesenchymal
markers such as vimentin, N-cadherin and ﬁbronectin. These
changes result in disruption of normal cell–cell adhesion, loss of
cellular polarity, remodeling of the cytoskeleton, and alteration in
cell–matrix adhesion, which collectively translate into enhanced
migratory, invasive and metastatic properties.4–7 PDAC cells that
assume the more mesenchymal phenotypes are also more
resistant to cytotoxic or cell-cycle disrupting therapeutics such
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as chemotherapy and MAPK inhibitors, partly explaining why
these treatments are neither very effective nor durable in
the clinic. Recent evidence also show that EMT is associated with
immune evasion and potentially resistance to immunotherapy.8
Therefore, targeting EMT represents a solid therapeutic strategy.
Several excellent reviews were published in recent years on the
underlying signaling mechanisms and role of EMT in
cancer,5–7,9–12 as well as the pathogenic role of stroma in
PDAC.2,3,13 However, a dedicated review on how stroma promotes
EMT in PDAC is lacking. In this study we critically reviewed seminal
and recent literature and provided a focused review on signaling
mechanisms by which distinct elements of stroma, namely CAFs,
ECM and hypoxia, promote EMT of PDAC cells. We shed light on
these complicated and interlocking mechanisms that collectively
drive EMT in PDAC.
EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
EMT is a dynamic, reversible process through which epithelial cells
assume a mesenchymal-like phenotype, deﬁned by changes in cell
morphology, acquisition of mesenchymal markers and migratory
function. The EMT process is orchestrated by a suite of
transcriptions factors (EMT-TFs) including Snai1 (Snail), Snai2
(Slug), Zeb1, Zeb2, and Twist.12,14 These TFs also happen to be
actively utilized by stem cells and progenitor cells during
embryonic development, but has later be shown to occur very
commonly in human cancers including PDAC.15,16 Instead of full
EMT, most cancer cells undergo various degrees and different
phenotypic versions of “partial” EMT, usually in response to
environmental clues, to adapt and survive. By re-expressing these
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Fig. 1 PDAC initiation and establishment of desmoplastic stroma. The desmoplastic stroma typically precedes and co-evolves with neoplastic
progression in PDAC. The stroma is characterized by diverse cellular and non-cellular components that undergo constant remodeling in
response to tumor progression and therapeutic intervention. In addition to intrinsic genetic mutations, a subset of PDAC cells engage the EMT
program under stromal clues and metastasize

stem cell markers, partial-EMT cells are sometimes dubbed as
being more “stem-like” in properties, which include less proliferative and more migratory capabilities. Acquisition of EMT also
alters the intrinsic cell death machineries that translate into
therapeutic resistance. Various signaling pathways are involved in
expression of the EMT-TFs, and these include the TGF-β, Notch,
Wnt/β-catenin and inﬂammatory JAK/STAT and NF-κb cascades.11
In a genetically engineered mouse model (GEMM, PDX-Cre;p53ﬂox/WT;
LSL-KRASG12D, aka KPC mice) of PDAC, lineage-tracing experiments
showed that EMT occurs at very early stage of neoplastic
progression way before emergence of frank PDAC tumors,
precipitated predominantly by inﬂammation.17
Speciﬁcally, chronic Inﬂammation promotes tumor progression
by changing the tumor microenvironment at the primary site of
neoplasia and promoting tumor invasion and dissemination.17,18
As the low grade pre-invasive lesion advanced to chronic
inﬂammation, various protumoral cellular and acellular (ﬁbrotic
tissue) factors are recruited in to the TME (details in the next
sections). The cellular components secrete various cytokines and
growth factors, whereas the acellular ﬁbrotic tissue increases
intertumoral pressure and formation of structurally and functionally abnormal blood vessels, resulting in severe hypoxia.19,20 These
changes promote EMT that endow the tumor cells with enhanced
invasiveness and metastatic capability.4,21 Importantly, studies of
human PDAC samples showed no statistical difference in the level
of desmoplasia between the primary and metastatic lesions.22
Analyses of GEMMs and human patients showed that PDAC
cells that have undergone EMT and extravasated to the circulation
retain EMT markers including vimentin and Zeb1.17,23 In addition,
studies in GEMMs showed that circulating PDAC cells that exhibit
EMT markers have stem-like properties, which allow them to
initiate tumor formation in distant sites.17 These studies show that
a subset of PDAC cells may retain an EMT or stem-like feature even
in the apparent absence of CAFs, at least for a short period of time
during distant metastasis. Importantly, EMT is reversible as cancer
cells retain the ability to revert to epithelial phenotype (MET, or
mesenchymal-epithelial transition) upon disengagement of these
environmental clues. Therefore, EMT is not entirely a binary
process, but instead is dynamic, pliable, and subject to ﬁne-tuning
by the environmental clues.

COMPONENTS OF PDAC TUMOR MICROENVIRONMENT (TME)
THAT DRIVE EMT
The desmoplastic stroma of PDAC can arise from the pre-existing
chronic inﬂammation that predispose and accompany neoplastic
progression,1,24 as well as cancer-associated inﬂammation (Fig. 1).
Patients with chronic pancreatitis are at increased risks for
developing PDAC.25 In PDAC GEMMs, chemical-induced acute or
chronic pancreatitis greatly accelerates the pace and enhances the
incidence of PDAC development.25–28 Conversely, precancerous or
neoplastic cells can themselves serve as inﬂammatory triggers to
the host immune system, stirring innate and adaptive inﬂammatory responses that further exacerbates the stromal reaction.26–30
CAFs are the major producers of ECM proteins, which consist
predominantly of collagens, ﬁbronectin, and laminin,31 although
recent evidence suggests PDAC cells can also contribute to
deposition of the ECM.32 Chronic, high-ordered structuring of
these ECM proteins results in a stiff, three-dimensional mesh
which, in combination with high molecular weight glycosaminoglycans such as hyaluronan, form a milieu with high interstitial
pressure that collapses blood vessels and limits delivery of oxygen
and nutrients.33,34 In addition to these biophysical properties, ECM
molecules have signaling function by triggering membrane
receptors on PDAC cells and engaging pathways that contribute
to EMT.31 In addition, CAFs secrete several humoral factors such as
TGF-β, IL-1α/β, IL-6, CXCL12, FGF, EGF, TNF-α,35–39 which promote
survival, proliferation and EMT of PDAC cells.39–43
Cancer-associated-ﬁbroblasts (CAFs)
Accurate identiﬁcation of CAFs has been a challenge in the ﬁeld.
Although markers such as alpha-smooth muscle actin (α-SMA),
ﬁbroblast-speciﬁc protein 1 (FSP1), ﬁbroblast activation protein
(FAP), and platelet-derived growth factor receptors alpha/beta
(PDGFRα/β), are commonly used to identify CAFs, these markers
are also be present in epithelial cells (not speciﬁc) and not
universally present in all CAFs populations (not sensitive). The
recent consensus from the Barbury Center Meeting held by
experts in the ﬁeld recommended that “cells negative for
epithelial, endothelial and leukocyte markers with elongated
morphology and lacking the mutations found within cancer cells
might be considered CAFs”.44 Furthermore, the consensus
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recommended that categorization of CAFs should be determined
mainly by function, informed by direct experimental evidence and
in some cancers, clinical correlations.44 Therefore, CAFs should be
studied in experimental conditions that maximally mimic the
actual TME, and also standardized to improve reproducibility.
Origins and subtypes of PDAC CAFs
CAFs are diverse in origin and heterogenous in subtypes and
function.45 Obtaining longitudinal human pancreas samples from
pre-malignant to malignant stages is practically impossible and
even if available, are typically limited in material and crosssectional in nature. Studies to deﬁne the origins of CAFs in PDAC
have mostly been done in GEMMs, but progress is stiﬂed by a lack
of truly CAF-speciﬁc markers to enable accurate lineage tracing.
Evidence from the constitutive or inducible KPC (Pdx-Cre/p53mut/wt/
LSL-KRASG12D) GEMMs showed that stromal ﬁbroblasts, deﬁned by
positive α-SMA staining, around the microscopic precancerous
lesions called pancreatic intraepithelial neoplasia (PanIN), undergo
expansion even before invasive PDAC clusters appear,46,47
suggesting that the bulk of CAFs probably originate from local
precursor ﬁbroblasts or pancreatic stellate cells,48 at least in early
stage of PDAC development. However, additional origins of CAFs
have been proposed in other cancer types, and these include
bone-marrow-derived mesenchymal stem cells (MSCs), or transdifferentiation from adipocytes,49,50 pericytes,51 smooth muscle
cells, and endothelial cells.52 However, direct evidence to support
derivation of PDAC CAFs from these origins is lacking.
Besides producing ECM, CAFs actively engage in reciprocal
signaling exchange with PDAC and the inﬁltrative immune cells
during tumor progression. For decades, most studies have shown
CAFs to be protumorigenic, based largely on co-culture and coinjection experiments.53,54 However, near global depletion of
stromal CAFs in GEMMs paradoxically accelerates PDAC progression by inducing immune-suppression, suggesting that CAFs have
both tumor-promoting and -restraining roles.55–58 The recent
advent of powerful single-cell techniques now revealed the
existence of different transcriptomic subtypes of CAFs, each with
distinct functions.59,60 Such functional diversiﬁcation of CAFs
appeared to be related to their distance from PDAC cells and
residing niche, and interestingly are interchangeable. Through
careful analyses of α-SMA and FAP expression in PDAC tumor
sections, Öhlund et al showed that dual α-SMA+ and FAP+ CAFs
(called myoﬁbrobasts or myCAFs) are in direct proximity to PDAC
cells. On the other hand, FAP+ CAFs that are located distant away
from PDAC cells stain weakly for α-SMA but instead express high
levels of inﬂammatory cytokines including IL-6, IL-1, and LIF, and
these are called inﬂammatory CAFs (iCAFs).59 It was proposed that
myCAFs are possibly tumor restrictive, whereas iCAFs promotes
tumor progression, partly explaining the observation that depletion of α-SMA+ CAFs accelerates PDAC progression in GEMMs.61
Importantly, these two phenotypes are interchangeable, based on
spatial and biochemical niche of culture conditions. For instance,
IL-1 was shown to induce conversion to iCAF by through the JAKSTAT pathway; whereas TGF-β downregulates expression of IL-1
receptor 1 expression (IL-1R1) and promotes conversion to
myCAFs.62 Therefore, JAK inhibition may be useful in blocking
conversion to iCAFs, which have protumorigenic properties.
However, addition of JAK1/2 inhibitor (ruxolitinib) to capecitabine
failed to improve overall survival in patients with metastatic
PDAC,63 highlighting the need to explore other targeted approach
to durably maintain the myCAF phenotype and curb the IL-1R
pathway. For the latter, targeting IRAK4, the master kinase
downstream of IL-1R signaling, represents a promising approach.
Silencing of IRAK4 in CAFs dramatically reduce the ability of CAFs
to secrete inﬂammatory cytokines and PDAC growth in vivo.54
Interestingly, using single-cell RNA sequencing in mouse PDAC
tumors, a third distinct CAF subtype was identiﬁed and termed
antigen- presenting CAFs (apCAFs). The apCAFs are also present in
Signal Transduction and Targeted Therapy (2020)5:249

human PDAC albeit in much smaller abundance. The apCAFs have
increased expression of MHC class II and therefore may be able to
present antigens to CD4+ T cells. However, lack of co-stimulatory
molecules on apCAFs may result in incomplete CD4+ T cell
activation. Therefore apCAFs are proposed to blunt anti-tumor
response by outcompeting the scarce dendritic cells for access to
CD4+ T cells.60 Signaling pathway leading to acquisition of apCAF
phenotype, and the strategies to conﬁrm the role of apCAFs which
is necessary for therapeutic intervention are still unclear.
Contributions of CAFs to EMT
The histological progression of PDAC is driven collectively by
PDAC cells and cell types that they subvert, particularly CAFs.
Because CAFs are not oncogenically mutated, their biological
outputs are passively controlled by adjacent PDAC cells, although
additional epigenetic modiﬁcation may enable them to behave
more autonomously.64 However, once subverted, CAFs can in turn
promotes the aggressiveness, including EMT, of PDAC cells.
Secreted factors from CAFs drive PDAC EMT
The PDAC TME is rife with various cytokines and chemokines
produced by CAFs, PDAC, and immune cells, and many of which
potent inducers of PDAC EMT (Fig. 2). Here we review the
signaling mechanism by which the best-described cytokines, TGFβ, IL-1, IL-6, and TNFα, induce EMT.65
TGF-β. Transforming growth factor-β (TGF-β) is a pleotropic
cytokine, which controls several cellular functions including EMT,
proliferation, and survival. In many cancer types including PDAC,
TGF-β is the major inducer of EMT.66 Engagement of the TGF-β
receptor complex (TGF-βRI/II) leads to phosphorylation of SMAD2
and SMAD3 transcription factors, which heterotrimerize with
SMAD4 and translocate into the nucleus to activate or repress
target genes67,68 (Fig. 3). In normal cells, TGF-β pathway activation
leads to cell-cycle arrest through SMAD-dependent downregulation of c-Myc leading to upregulated transcription of CDK
inhibitors p15 and p27, as well as abrogation of prereplication
complex, which causes G1/S arrest.69 Simultaneously, activated
SMAD2/3/4 drive transcription of several EMT-TFs including Snai1,
Snai2, Zeb1, Zeb2, and TWIST.70 This results in release of EMT cells
from the conﬁne of adjacent epithelial cells and basement
membrane, which can then migrate to distant organs to
differentiate and repopulate. Importantly, TGF-β signaling is
quenched by negative feedback mechanisms. For instance,
upregulation of inhibitory SMADs (SMAD6 and SMAD7) blocks
phosphorylation of SMAD3/4 and recruits E3 ligases Smurf1/2 to
degrade TGF-β receptors.71 Therefore, tightly regulated TGF-β
signaling ensures normal embryonic development, wound healing
process and tissue regeneration. In addition to the SMADs, TGF-β
ligation also leads to relatively rapid activation of RAS, ERK, TAK1,
JNK, p38 MAPK, and the IKK-NF-κB pathways, leading to
transcription of EMT-TFs and also TGF-β, providing another
mechanism that ampliﬁes TGF-β response.72,73 However, the
cellular context and exact mechanism by which these pathways
tune EMT remains poorly characterized in PDAC.
In PDAC, the impact of TGF-β signaling is highly dependent on
cellular context and concurrent genetic alterations.74 While on one
hand tumor-intrinsic TGF-β signaling is growth suppressive,
stromal TGF-β signaling leads to ﬁbrosis and immune escape. In
PDAC cells with intact SMAD signaling, TGF-β activation results in
engagement of EMT, which is accompanied by reduced proliferation and apoptosis.75,76 In support, pancreas-speciﬁc mono- or
biallelic deletion of TGFRII, which encodes the primary receptor for
TGF-β, cooperates with oncogenic KRASG12D in accelerating
development of aggressive PDAC in GEMMs,77 demonstrating
that tumor-intrinsic TGF-β signaling is tumor-suppressive. However, PDAC cells that eventually escaped the suppressive effect
of TGF-β have re-expressed ID1. ID1 is a pancreas progenitor gene,
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Fig 2 Collective contribution of CAFs and immune cells to EMT. CAFs interact with both the tumor cells and immune cells especially M2 TAMs
through secreted cytokines and chemokines, resulting in PDAC EMT

which encodes a helix-loop-helix (HLH) protein that heterodimerizes with bHLH transcription factors, and re-expression of ID1
protects PDAC cells from TGF-β-induced apoptosis.78 In 60% of
human PDAC, SMAD4 is silenced by allelic deletion, intragenic
mutation or epigenetic silencing, which correlate with widespread
metastasis.79 In PDAC GEMMs, pancreas-speciﬁc deletion of
SMAD4 cooperates with KRASG12D to accelerate development of
IPMN, a precancerous lesion, but progression to invasive PDAC
occurs at relatively low penetrance (2/12 mice).80,81 Importantly,
when further crossed with INK4a/Arfﬂox/ﬂox mice, SMAD4-null
KRASG12D PDAC tumors developed at higher frequency but
displayed signiﬁcantly more prominent epithelial identity including higher E-cadherin and lower Slug expression, upholding a role
of SMAD4 in promoting EMT.80 A recent report showed that
SMAD4-null PDAC cells survive TGF-β-induces apoptosis through
expression stem cell factor Sox4, which cooperates with Klf5, a
lineage survival factor, to restore tumor-initiating ability.76
These genetic models clearly demonstrate that tumor-intrinsic
TGF-β signaling is growth-prohibitive. However, the global impact
of TGF-β signaling is protumorigenic. In GEMM, global deletion of
TGFRII impedes PDAC development via inhibition of stromal
ﬁbrosis, and restoration of anti-tumor immune function,75
indicating that stromal TGF-β signaling is protumorigenic. In
support, nearly half of PDAC tumors showed enhanced TGF-β or
TGFRII expression by immunohistochemistry, which correlate with
poor survival,82,83 overall upholding the rationale for moving
systemic inhibition of PDAC in clinical trials, although the correct
combinations remain to be determined.

kinases which phospho-activate the STAT3 transcription factor.
Deletion of STAT3 signiﬁcantly lowered spontaneous and
caerulein-induced progression of PanIN to PDAC in GEMMs.87,88
Furthermore, lineage-tracing model showed that EMT precedes
frank tumor progression in GEMMs, which is greatly accelerated by
cerulean-induced inﬂammation.17 By inference, loss of STAT3 may
retard inﬂammation- induced EMT, but this remains to be
determined. Notably, the role of STAT3 in EMT is complex.
CRISPR/Cas9 ablation of STAT3 in murine KRASG12D/p53-null cells
results in formation of tumor xenografts that are anaplastic in
histology and displayed EMT characteristics including loss of
keratin, E-cadherin and acquisition of SMA and ACTA2.89
Mechanism leading to changes of these markers is unclear.
Remarkably, forced expression of phosphomimetic STAT3 S727E
mutant, but not wild-type or the hyperactive Y640F mutants,
induces partial-EMT phenotype evidenced by downregulation of
EpCAM, CD133 and a mixed epithelial-mesenchymal histology.89
Mechanistically, activated STAT3 enhances vimentin gene expression by binding to the antisilencer element upstream of vimentin
promoter, where it binds and overcome the repressor function of
ZBP-89 and allowing vimentin to be transcribed.90 Interestingly,
PDAC cells that have undergone EMT upregulates IL-6 transcription via TWIST to sustain tumor inﬂammation,91 and perhaps
further sustain EMT via autocrine JAK-STAT3 activation. Therefore,
the contribution of STAT3 to EMT is likely context dependent: proEMT in the setting of inﬂammation as in the presence of IL-6, but
sustained loss of STAT3 likely results in adaptive outgrowth of EMT
population through mechanisms that are largely unclear.

Interleukin-6. Interleukin-6 (IL-6) is a major inﬂammatory cytokine
that is required for RAS-induced tumorigenesis.84 In addition,
secretion of IL-6 by pancreatic stellate cells (PSCs) and myeloid
cells activates STAT3 signaling to promote progression from PanIN
to PDAC.85,86 Ligation of IL-6R results in phosphorylation of JAK

IL-1α/β and TNF-α. Constitutive activation of the NF-κB transcription factors is present in two third of PDAC and is tightly
associated with tumor ﬁbrosis, chemoresistance and poor prognosis in PDAC.92 One of the many important biological outputs
from NF-κB activation is induction of inﬂammation, a hallmark of
Signal Transduction and Targeted Therapy (2020)5:249
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Fig 3 Role of TGF-β, IL-6, and IL-1β signaling pathways in PDAC EMT.
a TGF-β signaling pathway can be SMAD-dependent or independent. In SMAD-dependent setting, TGF-β binds its receptor complex
(TGF-β receptors I/II dimer) and phosphorylate SMAD proteins and
subsequently transported into the nucleus to induce EMT-TFs.
Activation of TGFR can also engage MAPK and NF-kB signaling to
transactivate EMT-TFs. b Engagement of the IL-6R activates JAK
kinases which phospho-activate STAT3 transcription factor, leading
to upregulation of EMT-TFs. c Activation of IL-1R engages IRAK4TAK1 and the downstream NF-κB, JNK, and p38 MAPK cascades to
promote EMT

the PDAC TME and an important driving mechanism of EMT. In
fact, activation of the NF-κB cascade is required for KRAS-induced
PDAC development in GEMMs.93 Activation of the canonical NF-κB
cascade is driven by IRAK4-TAK1-IKK axis following engagement of
the IL-1R by autocrine and paracrine IL-1α and IL-1β secretion,
resulting in increased chemoresistance, invasion, and metastasis.54,92,94 TGF-β-induced EMT is also partly blocked by overexpression of dominant negative ikbα mutant, demonstrating the
contribution of the canonical NF-κB cascade in TGF-β-induced
EMT.95 Expression of TNF-α or activated IKK mutant induces EMT
through upregulation of vimentin, ZEB1, and downregulation of Ecadherin.95 In addition, TNF-α activates the NF-κB pathway,
leading to induction of COP9 signalosome 2 (CSN2), which blocks
ubiquitination and proteasomal degradation of Snail to promote
EMT.96 The NF-κB cascade can also be activated by overexpression
of IGFBP2, which degrades PTEN and activates the PI3K-AKT-IKK
axis, leading to downregulation of E-cadherin, upregulation of
vimentin and increased migration and invasion of PDAC cells.97
Therefore, targeting the NF-kB cascade at the convergent nodes
from these upstream receptors, particularly TAK1 and IKK kinases,
are promising therapeutic strategies, although effective, speciﬁc,
and safe TAK1 and IKK inhibitors are still not available.
Contributions of ECM to EMT
The dense desmoplastic stroma of PDAC contains a large amount
of EMC that includes the ﬁbrillar collagen, ﬁbronectin, laminin, as
well as proteoglycans such as hyaluronic acid (HA, or hyaluronan).
The building blocks for these ECM proteins are produced mainly
by CAFs, and to a much smaller degree, cancer cells. Besides
functioning as physical barrier, these elements have signaling
function that contributes to EMT of PDAC cells.
Collagens. Mass spectrophotometric studies of PDAC from
patient samples and GEMMs showed that collagens are the most
Signal Transduction and Targeted Therapy (2020)5:249

abundant, comprising 90% of ECM in PDAC. Of all the different
types of collagen, type I and III are the most prominent, whose
abundance increases during progression from PanIN to PDAC.32
The less abundant type IV collagen is the main component of
basement membrane which, along with laminin, separates PDAC
and endothelial cells from the remaining stroma.
Dense stromal deposition of type I and III collagens results in a
stiff TME that not only restricts neovascularization, but also shapes
the behavior of PDAC cells via various mechanotransduction
pathways.98 The integrins and discoidin domain receptor (DDR)
are two major families of cellular receptors that sense collagen in
the TME. The integrins are heterodimeric transmembrane
receptors that are formed by noncovalent association between
18 different α and 8 different β subunits, resulting in 24 members,
each with distinct ligand (collagen, ﬁbronectin and laminins)
recognition.99 Ligation with the ECM proteins results in clustering
of integrins, forming focal adhesions on the cell membrane where
the integrins utilize linkers such as vinculin and paxillin to connect
with intracellular actin cytoskeleton.100 Such ECM-actin interaction
results in activation of signaling pathways including the FAK/SFK,
Fyn/YES, and Rac/Cdc42 cascades that initiate EMT to facilitate
cellular migration.101 Speciﬁcally, FAK activates p130CAS/paxillin,
which in turns engages Rho GTPases to form focal adhesions
necessary for actin polymerization. Activated paxillin also activates
JNK kinase, which phosphorylates c-Jun transcription factor and
upregulation of N-cadherin.102,103 Another mechanism by which
FAK promotes EMT is via activation of Yes-associated protein (YAP)
and its homologous protein Transcriptional Co-Activator With
PDZ-Binding Motif (TAZ). Activated YAP-TAZ translocate to the
nucleus and interact with the TEA domain family members (TEAD)
to transactivate genes that drive EMT, which include RHOA, CDC42,
RAC, SLUG, SNAIL, and ZEB.104–106 Notably, formation of focal
adhesions is proportionate to the external mechanical force,107
and thus in the stiff PDAC TME these adhesion pathways are most
likely constantly engaged. In support, the epithelia of human and
murine PDAC exhibited strong activation of FAK by
phosphorylated-FAK staining, whereas this is almost absent in
normal epithelia. Pharmacologic suppression of FAK reduces
collagen deposition in KPC GEMM and potentiates response to
immunotherapy and chemotherapy.108
Besides the integrins, the discoidin domain receptors (DDR),
which consists of DDR1 and DDR2, are a family of receptor
tyrosine kinase that sense collagens. Stimulation of DDR1 with
collagens were reported to activate several signaling cascades
including PI3K/Akt and Ras/ERK MAPK pathways.109 In PDAC,
DDR1 and its downstream protein tyrosine kinase 2 (Pyk2) are
required, in addition to integrin signaling, in collagen-induced Ncadherin switch.102 Inhibition of DDR1 reduces collagen-induced
PDAC tumorigenicity via suppression of protein tyrosine kinase 2
(Pyk2) and pseudopodium-enriched atypical kinase 1 (PEAK1)
activation, thereby enhancing the effect of chemotherapy in
preclinical models.110
Fibronectin. Fibronectin (FN) is a high molecular weight glycoprotein composed of repeats of different type of FN isoforms
generated from alternative splicing of the ﬁbronectin premRNA.111 Fibronectin binds predominantly the integrins, especially integrin α5β1, to activate FAK and Rho GTPases to promote
EMT in various solid tumors.112 Although direct experimental
evidence linking ﬁbronectin and EMT is lacking in PDAC, similar
mechanisms are expected to be involved. In addition, ﬁbronectin
binds collagen and is expected to positively contribute to collagen
signaling and hence EMT in PDAC.
Hyaluronan. Investigation of HA as a therapeutic target in PDAC
biology has been of intense interest in recent years. Hyaluronan is
a high molecular weight linear glycosaminoglycan (GAG) that
consists of repeating N-acetyl glucosamine and glucuronic acid
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units assembled by the cytoplasmic HA synthases, HAS1, HAS2,
and HAS3.113 The growing HA polymers are extruded through the
plasma membrane into the extracellular space where they are
incorporated into the pre-existing ECM. On the other hand, HA is
degraded by hyaluronidases (HYAL1-4, HYALP1, and PH20). Of
these, HYAL1 and HYAL2 are widely distributed throughout tissues
and probably the main enzymes that degrade HA.113,114 The
accumulated HA matrix serves as a water-absorbent that
maintains tissue hydration and homeostasis. However, excessive
HA deposition, as commonly found in PDAC tumors, results in
high interstitial pressure that collapses tumor vasculature and
limits delivery of therapeutics.115 In support, high HA and HAS2
expression, and low HYAL1 expression were independent factors
associated with poor postoperative survival in PDAC patients.116 In
PDAC mouse model, addition of hyaluronidase reduces intratumoral hyaluronan content and interstitial pressure, which allows
re-expansion of the microvasculature and increases delivery of
chemotherapy into PDAC TME, thereby lengthening survival of
treated mice.117 Unfortunately, addition of pegylated PH20
(PEGPH20) to chemotherapy FOLFIRINOX or gemctabine/nabpaclitaxel failed to improve outcome of PDAC patients and will be
discussed in later section.
Besides its biophysical functions, HA instructs behavior of PDAC
cells through interactions with their surface receptors, especially
CD44 and receptor for HA‐mediated motility (RHAMM).118 Importantly, CD44 is one of the putative stem cell markers in PDAC,119
signifying its supportive role in EMT. Furthermore, decades of
studies showed that CD44 participates in almost every aspects of
malignant phenotypes of cancer cells,120 largely enabled by its
multifarious signaling capabilities. Besides the standard-length
isoform (CD44s), CD44 is alternatively spliced into variants
(CD44v1-10), which subsequently undergo modiﬁcations by N‐
and O‐linked glycosylation that affects their substrate binding
afﬁnity and speciﬁcity, and hence downstream signaling pathways.
Of all variants of CD44, CD44v6 has been shown to promote tumor
progression and metastatic spread in many solid tumors.121 CD44
can also undergo stepwise proteolytic cleavage by type 1 matrix
metalloprotease and γ-secretase, releasing a 12kDa intracellular
domain (ICD) that can translocate to the nucleus to transactivate
CD44, as well as genes that promote survival, oxidative glycolysis,
invasion, and stemness factors including NANOG, SOX2, OCT4 cMYC, and TWIST1.122–125 Upon HA binding, both CD44 and RHAMM
function as a co‐receptors to activate other transmembrane
tyrosine kinases, including epidermal growth factor receptor, c‐
MET, and platelet‐derived growth factor receptor to promote
tumor progression and therapeutic resistance.117,126,127 In addition,
CD44 and RHAMM ligation also activates kinases including ERK,
FAK, Src to promote cell migration, invasion, and survival.118,128–130
Importantly, downstream signaling and functional output of CD44
ligation is greatly dependent on the molecular weight of bound
HA.131 During inﬂammation and in cancer stroma, the turnover of
HA is enhanced, yielding richer species of medium and low
molecular weight HA. CD44 that binds to these species of HA are
more inclined to undergo proteolytic cleavage to yield CD44 ICD,
which is pro-EMT.132,133 Therefore, the HA-CD44 interaction is
clearly a major mechanism that drives EMT in PDAC, making it an
attractive therapeutic target.
Contributions of hypoxia to EMT
The combination of low perfusion, defective tumor vasculature
and enhanced intercellular competition for oxygen creates an
extremely hypoxic TME. Chronic hypoxia plays an active role in
promoting cancer aggressiveness and treatment resistance, in part
through promoting EMT.134 Adaptation to hypoxia is driven
mainly by hypoxia inducible factors (HIFs).135 HIFs are heterodimers consisting of an oxygen-sensitive α subunit (HIF-1α, HIF-2α,
and HIF-3α) and a constitutively expressed β subunit. In normoxia,
HIF-1α is hydroxylated, which enables it to bind and be

polyubiquitinated by the von Hippel-Lindau (VHL) E3 ligase and
targeted for proteasomal degradation. Hypoxia results in loss of
hydroxylation and subsequently stabilization and accumulation of
HIF-1α, which enters the nucleus, dimerizes with HIF-1β and
transactivates target genes. Notably, HIF-1α has been shown to
bind the hypoxia-responsive elements (HREs) in the promoter
region of EMT-TF genes including TWIST1, Snail, Slug, and ZEB1 to
drive EMT.134,136 Interestingly, co-expression of HIF-1α and Slug to
mimic hypoxia more readily induces EMT signaling and migratory
potential in PDAC population that are more stem-like, as
determined by expression levels of ALDH, E-cadherin, and
vimentin,137 indicating that hypoxia may cooperate with other
environmental and cell-intrinsic processes to intensify EMT.
Another mechanism by which hypoxia may promote EMT is via
sustaining NOTCH signaling. In this setting, hypoxia stabilizes
Notch 1 intracellular domain (ICD), which recruits HIF-1α and binds
to Notch-responsive promoters to transactivate Notch target
genes including HEY-2 and PGK1 to maintain stem cell state.138
Contributions of immune cells to EMT
The PDAC TME is rife with various kinds of immune cells,
particularly myeloid cells, which play an active role in maintaining
desmoplasia and stiﬂe anti-tumor response. Profound numbers of
tumor-associated macrophages (TAMs) accumulate during PDAC
progression.1 TAMs can originate from embryonic development,
which is the main source of pancreas-resident macrophages, and
expand through in situ proliferation where they exhibit a
proﬁbrotic transcriptional proﬁle, indicative of their roles in
cancer-related inﬂammation, immune escape, matrix remodeling,
and metastasis.139,140 Monocyte-derived TAMs play potent roles in
antigen presentation and can differentiate into antitumorigenic
M1- or (protumorigenic) M2-phenotypes. Notably, CAFs promote
an immunosuppressive microenvironment through induction and
accumulation of M2-polarized TAMs.141 CAF-derived chemokine
(C-X-C motif) ligand 12 (CXCL12)142–144 and macrophage colonystimulating factor (M-CSF)40,145 are well reported factors that
effectively recruit monocytes to the tumor tissue. Furthermore,
CAF-derived IL-6 and GM-CSF cooperate to induce transdifferentiation of tumor-resident macrophages to M2 macrophages.146–148 Therefore, the iCAFs are more likely the subpopulation that induces M2 polarization, although this will need to be
veriﬁed by direct experimental evidence. In addition, the hypoxic
tumor microenvironment can also triggers M2-polarized TAMs.149–151
Once polarized, M2 TAMs secrete various growth factors and
cytokines, including TGF-β,152,153 interleukin-IL-10, IL-6, TNFα,40,154,155 IL-1β,156,157 migration inhibitory factor (MIF)158, and
chemokines such as CCL20,159 which are all capable of promoting
EMT as previously described. In addition, gemcitabine treatment
results in robust inﬁltration of M2-polarized TAMs which secrete
TNFα, TGF-β, and IL-6, leading to EMT of PDAC cells.160 Therefore,
tumor inﬁltrative M2 TAMs are another major propeller of PDAC
EMT via providing various cytokines and chemokines.
PRECLINICAL MODELS TO STUDY EMT
Genetically engineered mouse models (GEMMs)
Studies of PDAC is greatly accelerated by the availability of
powerful GEMMs that recapitulates the oncogenic events and
histologic progression of human PDAC. The most widely used KPC
GEMM and their variants develop precancerous PanIN lesions at
almost 100% penetrance at 8–10 weeks of age, and progress to
developing locally advanced PDAC with dense desmoplasia at
16 weeks of age. The median survival of the KPC mice is around
5 months with the majority of mice developing malignant ascites
and distant organ metastases.47 Notably, lineage-traced KPC
model showed that a signiﬁcant portion of PDAC cells have
undergone EMT, evidenced by increased ZEB1 and decreased Ecadherin expression, and metastasized to the liver, in early PanIN
Signal Transduction and Targeted Therapy (2020)5:249
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Fig. 4 Summary of advantages and limitations of currently available preclinical models of PDAC. Desmoplastic stroma is a typical
characteristic of pancreatic cancer tumor microenvironment that promote epithelial-to-mesenchymal transition (EMT) and therapeutic
resistance. Improvement of in vitro models that include stromal cells including CAFs and immune cells should be increasingly incorporated to
identify therapeutic strategies that can be further tested in mouse models

stages.17 In contrary, using single-cell technology, PDAC cell
population with mesenchymal signature was enriched in late, but
not early stage PDAC tumors arising from Ptf1a-Cre;INK4aﬂox/ﬂox;
LSL-KRASG12 (or KIC) and in Pdx1-Cre;TP53ﬂox/ﬂox;LSL-KRASG12(KPfC)
mice.161 Such discrepancy probably arises from the difference in
deﬁnition of EMT in these two studies. It is critical to realize that
EMT is a highly dynamic process that encompasses a wide
spectrum of partial-EMT states.10,12 Therefore, changes in protein
marker such as ZEB1 and E-cadherins protein expression, as
described,17 may reﬂect a partial-EMT state where PDAC cells have
not fully assumed the mesenchymal transcriptomic proﬁle,161 but
nonetheless are able to migrate and metastasize.
Importantly, the GEMMs also allow studies of intratumoral CAFs
and immune cells during PDAC progression and will remain a
powerful tool. Despite these advantages, the KPC models are
costly, time-consuming, and labor intensive, limiting their use by
most labs and for large scale drug or genetic screening. In
addition, these GEMMs are typically driven by only few oncogenic
events, typically deletion of a tumor suppressor and introduction
of KRASG12D, which do not reﬂect the genetic complexities of
human PDAC. Therefore, in vitro human models that more closely
recapitulate the heterotypic nature and biophysical environment
of PDAC should be developed. As present stage, the traditional
monolayer cell culture is still the most widely used method to
study various aspects of PDAC biology, with considerable success
in the pass. However, it is now increasingly clear that the behavior
of PDAC cells and their response to genetic manipulation and
therapeutic challenge is highly dependent on the culture
condition and surrounding stromal cells.162,163 To this end,
different heterotypic models to simulate native PDAC have been
developed163–166 (Fig. 4).
Signal Transduction and Targeted Therapy (2020)5:249

Heterotypic human cell co-culture models
A commonly adopted way to mimic the PDAC TME is by coculturing differentially labelled, usually by ﬂuorescence, PDAC cells
and CAFs in monolayer cultures. These two cell types can be
cultured with or without direct physical contact. For the former,
PDAC cells and CAFs in ﬁxed ratio are layered one on top of the
other, or mingled, both of which allows bidirectional physical
interactions. For the latter, these two cell types are housed in
separate chambers (such as transwell systems) and cell–cell
communication occurs only through diffusion of humoral factors.
By mixed co-culture method, Ligorio et al. showed that secreted
factors from CAFs can diversify PDAC into proliferative, EMT or
double positive (DP) proliferative/EMT phenotypes, using singlecell RNAseq. The degree of diversiﬁcation into these phenotypes is
affected by the ratio of co-cultured CAFs. Mice injected with highstroma mixture (90% CAFs:10% PDAC cells) developed more
metastatic tumors that exhibit DP phenotype. Acquisition of EMT
or DP phenotype is driven predominantly by TGF-β secreted from
CAFs. In support, in human PDAC samples the DP phenotype is
enriched in high-stroma tumors,163 whereas EMT phenotype is
enriched in medium-stroma tumors. This study demonstrates that
a relatively simple co-culture method, if conducted methodically
and correlated carefully with human PDAC samples, can still
faithfully recapitulate some aspects of real PDAC tumors. However,
as recommended in the Banbury Center Consensus Statement,44
this relatively simple co-culture method can be further optimized
by inclusion of matrices such as collagen, laminin, hyaluronan, as
well as introduction of hypoxic and low serum conditions.
Spheroids. In actual tumors, PDAC cells are embedded threedimensionally within the stroma. Following EMT, extravasated
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PDAC cells circulate within the blood stream as three-dimensional
heterotypic clusters or single cells. Therefore, culturing PDAC cells
in aggregates, or spheroids, as suspension is one-step closer to
mimicking the real PDAC. In fact, basal oncogenic signaling and
adaptive response to therapeutics are different when cancer cells
are cultured in monolayer vs. three-dimentional (3D) spheroids.167,168 In addition, PDAC cells cultured as 3D spheroids
produce more matrices, become more glycolytic and expresses
more chemo-resistant genes compared to when grown as
monolayers.169 PDAC cells with intact TGF-β signaling machinery
assume more EMT phenotype when cultured as spheroids
compared to monolayer culture.170 However, PDAC cells are also
under constant interaction with surrounding cell types, and this
can by mimicked by inclusion of CAFs, vascular endothelial cells
and immune cells at various ratio to form heterotypic spheroids.171 Furthermore, addition of ECM matrices in the culture is
commonly used to increase stiffness of the culture media. Several
platforms such as Geltrex,172,173 biologically inert 3D alginate
scaffolds174 and magnetic 3D bioprinting protocols175 have been
developed to systematize spheroid generation and these are
greatly helpful in high-throughput drug screens.
Organoids. In PDAC tumors, neoplastic ductal cells typically form
single or multilayered epithelia with some degree of apical-basal
polarity, forming dysfunctional ductal-like structures that are
externally surrounded by basal membrane. During EMT, neoplastic
cells further lose cellular polarity, breach the basement membrane, and invade into the vasculatures to metastasize. These are
important cellular processes that cannot be recapitulated with
monolayer or spheroid models. Culture method to isolate, grow,
and propagate PDAC tumors with preserved cellular polarity and
tissue architecture (termed organoids) were successfully developed by the Tuveson and Clevers groups using resected or
biopsied human PDAC tissues.176 These PDAC organoids preserve
the proteomic and transcriptomic features, and importantly their
response to therapeutics that parallel their hosts in the clinic,177
making it currently the most powerful in vitro model with the
closest proximity to primary PDAC. Moreover, single-cell transcriptomics showed that CAFs that were co-cultured with PDAC
organoids, exhibited at least three different interchangeable
subtypes: iCAFs, myCAFs, and apCAFs.59,60 However, establishment and expansion of PDAC organoids from biopsy samples
typically takes weeks to months, require very speciﬁc cocktail of
growth factors and Matrigel, and highly trained personnel to
maintain the intratumoral heterogeneity. These caveats greatly
limit the adoption of this technique in most research labs and
must be overcome. Nonetheless, the organoid model has certainly
gained traction in recent years for drug screening and personalized medicine.178
THERAPEUTIC TARGETING OF PDAC STROMA: RECENT
LESSONS
It is widely accepted that PDAC stroma contributes to the poor
outcome of PDAC ranging from EMT, metastasis, chemoresistance
and immune evasion and is covered by a very nice review by
Hosein et al.2 The major causes that underlie the poor prognosis of
PDAC is extreme resistance to chemotherapy and early dissemination. In addition, PDAC has a much higher propensity to
disseminate, compared to other cancer types such as lung and
colon cancers that share similar oncogenic mutations. Lineage
tracing in GEMMs showed that PDAC cells undergo EMT and
metastasize even before formation of frank tumors, and these
processes can be accelerated by inﬂammation.17 Similarly,
circulating tumor cells are detected in most PDAC patients at
any stage.179 A nice review by Kalluri and Weinberg proposed
three different types of EMT.180 Type II EMT was precipitated by
chronic inﬂammation and ﬁbrosis, which (1) provide humoral

factors that promote EMT, and (2) disrupt tissue architecture
thereby allowing EMT cells to escape. Therefore, chronic
inﬂammation and the associated ﬁbrosis contribute to the
aggressive nature of PDAC starting from early stage. However,
strategies that targeting the stroma component of PDAC have
unfortunately failed in large scale clinical trials. In particular,
addition of pegylated hyaluronidase (PEGPH20) to chemotherapy
(FOLFIRINOX or Gemcitabine/Abraxane) failed to improve patient
survival in large scale clinical studies,181,182 despite promising
results in GEMMs.117 Although disappointing, these studies also
provided precious lessons for future improvement. First, the
content of PDAC ECM is highly dynamic and consists of several
matrix proteins that may compensate for reduced hyaluronan
abundance. Second, hyaluronan is a rapidly turned over proteoglycan, synthesized by three different hyaluronan synthases
(HAS1-3). It is possible that in clinical trials the administered
PEGH20 dose, hindered by side effects including gastrointestinal
toxicities and thromboembolic events when combined with
chemotherapy, was inadequate to outpace hyaluronan synthesis.
Third, degradation of hyaluronan may results in a surplus of low
and medium molecular weight hyaluronan species that still
activate CD44 and induce protective EMT. Fourth, the overall
utility of KPC GEMMs in predicting clinical response should be
carefully reconsidered, especially since several promising therapeutic strategies published based on these models have so far
failed to translate into clinical success. While the KPC GEMMs have
unquestionably contributed enormously to the understanding of
PDAC biology that cannot otherwise be achieved with conventional cell lines, patient-derived xenografts or other in vitro
models, it is equally important to improve human cell-based
models using various strategies to complement knowledge
derived from GEMMs. Fifth, therapeutic strategies that target
critical signaling pathways in both PDAC and CAFs should be
developed. For example, inhibition of focal adhesion kinase (FAK)
markedly reduces stromal collagen and also sensitizes PDAC cells
to chemotherapy.108 Targeting the NF-κB pathway through
suppressing Interleukin-1 receptor associated kinase 4 (IRAK4)
sensitizes PDAC cells to genotoxic stress and simultaneously
lowers the ability of CAFs to deposit collagen and foster tumor
ﬁbrosis, leading to improved response to chemotherapy.54,92,183
CONCLUSIONS AND PROSPECTS
PDAC is currently the only major cancer type that has not
beneﬁted from targeted or immune-based therapies, despite
decades of research and extensive publications. Recent modest
improvement in survival of PDAC patients results almost
exclusively from improvement in chemotherapy and perioperative
care. An important factor that must be critically re-examined is the
methodologies that are widely used to studying this histologically
complicated cancer type. The dense stroma of PDAC plays a very
active role in modulating the behavior and therapeutic response
of PDAC cells, and induction of EMT as we reviewed here, is merely
one of many recalcitrant facets of PDAC. Therefore, incorporation
on stromal elements including CAFs, ECM and immune cells and
proper culture conditions including hypoxia and low serum,
should be increasingly adopted in future studies of any signaling
pathway in PDAC. A robust, 3D heterotypic human cell-based
culture model should also be established for unbiased highthroughput screens and drug discovery. Importantly, the experimental models should be cost-effective, standardized and
reproducible, all of which require extensive discussion and
establishment of consensus or guidelines by experts in the ﬁeld,
as has been done for CAF44 and EMT12 research. To increase the
chance of future success, any novel therapeutic regimens should
be rigorously tested and shown to be effective in both heterotypic
human culture models and GEMMs before being advanced into
clinical trials.
Signal Transduction and Targeted Therapy (2020)5:249
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